Rare Disease Grants in Australia: Funding Research and Support for Rare Conditions

Rare diseases affect fewer than 1 in 2000 people individually — but collectively, they affect approximately 8% of Australians (over 2 million people). Most rare diseases are genetic, many are serious and progressive, most have no cure, and nearly all are underfunded relative to their individual and collective impact. Understanding the funding landscape helps rare disease patient organisations, researchers, families, and funders navigate this complex ecosystem.

The rare disease challenge

Scale

  • Over 7,000 known rare diseases
  • Approximately 2 million Australians affected (1 in 12)
  • 50% of cases affect children
  • 30% of children with a rare disease will die before age 5
  • Only 5-10% have any approved treatment

Impact

  • Average 5-year delay to diagnosis (diagnostic odyssey)
  • Limited treatment options — most are off-label or investigational
  • High out-of-pocket costs
  • Fragmented care (patients see many specialists, often without coordination)
  • Social isolation (rare disease communities are small)
  • Caregiver burden (often parents of affected children)

Research investment gap

Rare diseases attract proportionally far less research investment than common diseases — the "orphan" drug and research problem:
- Small patient populations make clinical trials difficult
- Limited commercial incentive for industry
- Government research agencies struggle to prioritise across thousands of conditions

Key rare disease funding bodies

NHMRC

The National Health and Medical Research Council funds some rare disease research:
- Open competitive grant rounds (rare disease proposals compete with all others)
- Specific rare disease initiatives (some targeted calls)
- Investigator grants for rare disease researchers
- Centres of Research Excellence

Rare Voices Australia

Rare Voices Australia is the peak body for the rare disease community:
- Advocacy for policy and research investment
- Patient organisation support
- Government engagement
- Not primarily a grantmaker but a connector and advocate

National Institutes of Health (NIH) and international

Australian researchers compete for NIH grants — significant source of rare disease research funding.

Medical Research Future Fund (MRFF)

MRFF has funded rare disease research through specific initiatives:
- Rare Diseases Mission
- Genetic research
- Genomics for diagnosis

Genomics and precision medicine investment

Australian Genomics and state genomics initiatives fund genetic rare disease diagnosis and research.

Disease-specific foundations

Each major rare disease has one or more charitable foundations:

Examples by condition

  • Cystic Fibrosis: Cystic Fibrosis Community Care, Cystic Fibrosis Australia
  • Muscular Dystrophy: Muscular Dystrophy Australia
  • MPS (Mucopolysaccharidoses): MPS Australia
  • Rett Syndrome: Rett Syndrome Association Australia
  • Fragile X: Fragile X Association of Australia
  • Tuberous Sclerosis: Tuberous Sclerosis Australia
  • Spinal Muscular Atrophy: SMA Australia
  • Neurofibromatosis: Neurofibromatosis Australia
  • Epidermolysis Bullosa: EB Research Foundation Australia
  • Primary Immune Deficiency: IDFNZ/IDFA equivalents

These foundations are simultaneously:
- Patient and family support organisations
- Research funders (disease-specific grants)
- Advocacy organisations (TGA, PBS listing, policy)
- Community builders

NDIS and rare disease

Many people with rare diseases have disabilities — and may access NDIS support:
- NDIS covers supports related to functional impact of rare conditions
- Planning for NDIS can be complex for rare disease given fluctuating needs
- Some rare disease organisations provide NDIS navigation support

Types of funded programmes

Research grants

Disease-specific foundation research grants:
- Laboratory research
- Clinical studies
- Natural history studies (characterising disease course)
- Biobank development
- Clinical trial support
- Registry development

Patient registries

National patient registries enable research by connecting researchers with patients:
- Registry development and maintenance
- Patient consent and data management
- International registry collaboration

Diagnostic support

Reducing the diagnostic odyssey:
- Genetic counselling
- Whole genome/exome sequencing
- Rare disease diagnostic clinics
- International diagnostic consultation

Patient and family support

  • Support groups (national and regional)
  • Peer connection (families caring for a child with the same condition)
  • Counselling and psychological support
  • Respite care for carers
  • Financial hardship grants (out-of-pocket costs)

Awareness and advocacy

  • Rare Disease Day (last day of February) events
  • Government advocacy for orphan drug access
  • Media awareness campaigns
  • Medical professional education

Workforce development

Training doctors and allied health in rare disease:
- Rare disease training for GPs
- Allied health rare disease resources
- Telemedicine for rare disease (connecting patients to distant specialists)

Grant application considerations for rare disease

The numbers problem

Small patient populations mean small numbers of beneficiaries. Funders used to large-scale programmes may struggle with proposals benefiting 20 or 50 families. Address this head-on: explain the severity of impact, the absence of alternatives, and the leverage of research (one breakthrough benefits all patients globally).

Research to treatment pipeline

Funders with finite resources are more compelling when research has a plausible pathway to treatment. Show how proposed research could lead to treatment development.

International collaboration

Many rare disease research programmes are international by necessity — small patient populations require multisite studies. Show international collaborations.

Community voice

Rare disease patient organisations are often family-founded and community-led — this lived experience leadership is a strength, not a weakness. Feature it.

Long-term commitment

Rare disease research requires long-term commitment — not one-year grants but sustained investment. Where possible, show multi-year funding or committed organisational sustainability.


Tahua's grants management platform supports disease-specific foundations and rare disease funders — with research grant management, patient registry support, family support programme tracking, and the reporting tools that help rare disease funders demonstrate their contribution to better outcomes for Australia's rare disease community.

Book a conversation with the Tahua team →